Copyright Reports & Markets. All rights reserved.

Global Female Hypoactive Sexual Desire Disorder Therapeutics Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Female Hypoactive Sexual Desire Disorder Therapeutics Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Female Hypoactive Sexual Desire Disorder Therapeutics Market Size Growth Rate by Product
      • 1.4.2 BP-101
      • 1.4.3 Bremelanotide
      • 1.4.4 Gepirone Hydrochloride ER
      • 1.4.5 PVT-011
      • 1.4.6 Others
    • 1.5 Market by End User
      • 1.5.1 Global Female Hypoactive Sexual Desire Disorder Therapeutics Market Size Growth Rate by End User
      • 1.5.2 Out-Patient
      • 1.5.3 In-Patient
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Female Hypoactive Sexual Desire Disorder Therapeutics Market Size
      • 2.1.1 Global Female Hypoactive Sexual Desire Disorder Therapeutics Revenue 2014-2025
      • 2.1.2 Global Female Hypoactive Sexual Desire Disorder Therapeutics Sales 2014-2025
    • 2.2 Female Hypoactive Sexual Desire Disorder Therapeutics Growth Rate by Regions
      • 2.2.1 Global Female Hypoactive Sexual Desire Disorder Therapeutics Sales by Regions
      • 2.2.2 Global Female Hypoactive Sexual Desire Disorder Therapeutics Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Female Hypoactive Sexual Desire Disorder Therapeutics Sales by Manufacturers
      • 3.1.1 Female Hypoactive Sexual Desire Disorder Therapeutics Sales by Manufacturers
      • 3.1.2 Female Hypoactive Sexual Desire Disorder Therapeutics Sales Market Share by Manufacturers
      • 3.1.3 Global Female Hypoactive Sexual Desire Disorder Therapeutics Market Concentration Ratio (CR5 and HHI)
    • 3.2 Female Hypoactive Sexual Desire Disorder Therapeutics Revenue by Manufacturers
      • 3.2.1 Female Hypoactive Sexual Desire Disorder Therapeutics Revenue by Manufacturers (2014-2019)
      • 3.2.2 Female Hypoactive Sexual Desire Disorder Therapeutics Revenue Share by Manufacturers (2014-2019)
    • 3.3 Female Hypoactive Sexual Desire Disorder Therapeutics Price by Manufacturers
    • 3.4 Female Hypoactive Sexual Desire Disorder Therapeutics Manufacturing Base Distribution, Product Types
      • 3.4.1 Female Hypoactive Sexual Desire Disorder Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Female Hypoactive Sexual Desire Disorder Therapeutics Product Type
      • 3.4.3 Date of International Manufacturers Enter into Female Hypoactive Sexual Desire Disorder Therapeutics Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Female Hypoactive Sexual Desire Disorder Therapeutics Sales by Product
    • 4.2 Global Female Hypoactive Sexual Desire Disorder Therapeutics Revenue by Product
    • 4.3 Female Hypoactive Sexual Desire Disorder Therapeutics Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Female Hypoactive Sexual Desire Disorder Therapeutics Breakdown Data by End User

    6 North America

    • 6.1 North America Female Hypoactive Sexual Desire Disorder Therapeutics by Countries
      • 6.1.1 North America Female Hypoactive Sexual Desire Disorder Therapeutics Sales by Countries
      • 6.1.2 North America Female Hypoactive Sexual Desire Disorder Therapeutics Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Female Hypoactive Sexual Desire Disorder Therapeutics by Product
    • 6.3 North America Female Hypoactive Sexual Desire Disorder Therapeutics by End User

    7 Europe

    • 7.1 Europe Female Hypoactive Sexual Desire Disorder Therapeutics by Countries
      • 7.1.1 Europe Female Hypoactive Sexual Desire Disorder Therapeutics Sales by Countries
      • 7.1.2 Europe Female Hypoactive Sexual Desire Disorder Therapeutics Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Female Hypoactive Sexual Desire Disorder Therapeutics by Product
    • 7.3 Europe Female Hypoactive Sexual Desire Disorder Therapeutics by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Female Hypoactive Sexual Desire Disorder Therapeutics by Countries
      • 8.1.1 Asia Pacific Female Hypoactive Sexual Desire Disorder Therapeutics Sales by Countries
      • 8.1.2 Asia Pacific Female Hypoactive Sexual Desire Disorder Therapeutics Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Female Hypoactive Sexual Desire Disorder Therapeutics by Product
    • 8.3 Asia Pacific Female Hypoactive Sexual Desire Disorder Therapeutics by End User

    9 Central & South America

    • 9.1 Central & South America Female Hypoactive Sexual Desire Disorder Therapeutics by Countries
      • 9.1.1 Central & South America Female Hypoactive Sexual Desire Disorder Therapeutics Sales by Countries
      • 9.1.2 Central & South America Female Hypoactive Sexual Desire Disorder Therapeutics Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Female Hypoactive Sexual Desire Disorder Therapeutics by Product
    • 9.3 Central & South America Female Hypoactive Sexual Desire Disorder Therapeutics by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Female Hypoactive Sexual Desire Disorder Therapeutics by Countries
      • 10.1.1 Middle East and Africa Female Hypoactive Sexual Desire Disorder Therapeutics Sales by Countries
      • 10.1.2 Middle East and Africa Female Hypoactive Sexual Desire Disorder Therapeutics Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Female Hypoactive Sexual Desire Disorder Therapeutics by Product
    • 10.3 Middle East and Africa Female Hypoactive Sexual Desire Disorder Therapeutics by End User

    11 Company Profiles

    • 11.1 Emotional Brain BV
      • 11.1.1 Emotional Brain BV Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Emotional Brain BV Female Hypoactive Sexual Desire Disorder Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Emotional Brain BV Female Hypoactive Sexual Desire Disorder Therapeutics Products Offered
      • 11.1.5 Emotional Brain BV Recent Development
    • 11.2 GlaxoSmithKline Plc
      • 11.2.1 GlaxoSmithKline Plc Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 GlaxoSmithKline Plc Female Hypoactive Sexual Desire Disorder Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 GlaxoSmithKline Plc Female Hypoactive Sexual Desire Disorder Therapeutics Products Offered
      • 11.2.5 GlaxoSmithKline Plc Recent Development
    • 11.3 Palatin Technologies Inc
      • 11.3.1 Palatin Technologies Inc Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Palatin Technologies Inc Female Hypoactive Sexual Desire Disorder Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Palatin Technologies Inc Female Hypoactive Sexual Desire Disorder Therapeutics Products Offered
      • 11.3.5 Palatin Technologies Inc Recent Development
    • 11.4 Pivot Pharmaceuticals Inc
      • 11.4.1 Pivot Pharmaceuticals Inc Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Pivot Pharmaceuticals Inc Female Hypoactive Sexual Desire Disorder Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Pivot Pharmaceuticals Inc Female Hypoactive Sexual Desire Disorder Therapeutics Products Offered
      • 11.4.5 Pivot Pharmaceuticals Inc Recent Development
    • 11.5 Strategic Science & Technologies LLC
      • 11.5.1 Strategic Science & Technologies LLC Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Strategic Science & Technologies LLC Female Hypoactive Sexual Desire Disorder Therapeutics Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Strategic Science & Technologies LLC Female Hypoactive Sexual Desire Disorder Therapeutics Products Offered
      • 11.5.5 Strategic Science & Technologies LLC Recent Development

    12 Future Forecast

    • 12.1 Female Hypoactive Sexual Desire Disorder Therapeutics Market Forecast by Regions
      • 12.1.1 Global Female Hypoactive Sexual Desire Disorder Therapeutics Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Female Hypoactive Sexual Desire Disorder Therapeutics Revenue Forecast by Regions 2019-2025
    • 12.2 Female Hypoactive Sexual Desire Disorder Therapeutics Market Forecast by Product
      • 12.2.1 Global Female Hypoactive Sexual Desire Disorder Therapeutics Sales Forecast by Product 2019-2025
      • 12.2.2 Global Female Hypoactive Sexual Desire Disorder Therapeutics Revenue Forecast by Product 2019-2025
    • 12.3 Female Hypoactive Sexual Desire Disorder Therapeutics Market Forecast by End User
    • 12.4 North America Female Hypoactive Sexual Desire Disorder Therapeutics Forecast
    • 12.5 Europe Female Hypoactive Sexual Desire Disorder Therapeutics Forecast
    • 12.6 Asia Pacific Female Hypoactive Sexual Desire Disorder Therapeutics Forecast
    • 12.7 Central & South America Female Hypoactive Sexual Desire Disorder Therapeutics Forecast
    • 12.8 Middle East and Africa Female Hypoactive Sexual Desire Disorder Therapeutics Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Female Hypoactive Sexual Desire Disorder Therapeutics Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Female Hypoactive Sexual Desire Disorder Therapeutics market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Female Hypoactive Sexual Desire Disorder Therapeutics market based on company, product type, end user and key regions.

      This report studies the global market size of Female Hypoactive Sexual Desire Disorder Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Female Hypoactive Sexual Desire Disorder Therapeutics in these regions.
      This research report categorizes the global Female Hypoactive Sexual Desire Disorder Therapeutics market by top players/brands, region, type and end user. This report also studies the global Female Hypoactive Sexual Desire Disorder Therapeutics market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Emotional Brain BV
      GlaxoSmithKline Plc
      Palatin Technologies Inc
      Pivot Pharmaceuticals Inc
      Strategic Science & Technologies LLC

      Market size by Product
      BP-101
      Bremelanotide
      Gepirone Hydrochloride ER
      PVT-011
      Others
      Market size by End User
      Out-Patient
      In-Patient

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Female Hypoactive Sexual Desire Disorder Therapeutics market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Female Hypoactive Sexual Desire Disorder Therapeutics market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Female Hypoactive Sexual Desire Disorder Therapeutics companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Female Hypoactive Sexual Desire Disorder Therapeutics submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Female Hypoactive Sexual Desire Disorder Therapeutics are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Female Hypoactive Sexual Desire Disorder Therapeutics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now